Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2022

Feb 08, 2023

BUY
$0.32 - $0.5 $776 - $1,213
2,426 Added 34657.14%
2,433 $0
Q3 2022

Nov 10, 2022

SELL
$0.4 - $0.59 $3,058 - $4,511
-7,647 Reduced 99.91%
7 $0
Q2 2022

Aug 10, 2022

BUY
$0.44 - $0.97 $156 - $344
355 Added 4.86%
7,654 $4,000
Q1 2022

May 16, 2022

BUY
$0.82 - $1.13 $4,697 - $6,473
5,729 Added 364.9%
7,299 $7,000
Q4 2021

Feb 14, 2022

BUY
$0.92 - $2.2 $1,437 - $3,438
1,563 Added 22328.57%
1,570 $2,000
Q3 2021

Nov 15, 2021

SELL
$2.15 - $3.92 $12,093 - $22,050
-5,625 Reduced 99.88%
7 $0
Q2 2021

Aug 13, 2021

BUY
$3.75 - $5.17 $21,093 - $29,081
5,625 Added 80357.14%
5,632 $22,000
Q1 2021

May 12, 2021

SELL
$3.94 - $6.43 $78 - $128
-20 Reduced 74.07%
7 $0
Q4 2020

Feb 11, 2021

SELL
$3.68 - $11.02 $2,859 - $8,562
-777 Reduced 96.64%
27 $0
Q3 2020

Nov 12, 2020

BUY
$10.51 - $23.79 $8,334 - $18,865
793 Added 7209.09%
804 $9,000
Q2 2020

Jul 31, 2020

SELL
$6.3 - $11.35 $9,298 - $16,752
-1,476 Reduced 99.26%
11 $0
Q1 2020

May 01, 2020

BUY
$5.4 - $12.93 $1,695 - $4,060
314 Added 26.77%
1,487 $10,000
Q4 2019

Feb 14, 2020

BUY
$5.47 - $11.33 $6,416 - $13,290
1,173 New
1,173 $10,000

Others Institutions Holding LMNL

About Liminal BioSciences Inc.


  • Ticker LMNL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 31,042,600
  • Description
  • Liminal BioSciences Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel small molecule drug therapeutics for inflammatory, fibrotic, and metabolic diseases in Canada and the United Kingdom. The company's lead product candidate is fezagepras (PBI-4050), which has been completed Phase I clinical trial for the trea...
More about LMNL
Track This Portfolio

Track Ubs Group Ag Portfolio

Follow Ubs Group Ag and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Group Ag with notifications on news.